Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 3 randomized open-label study of tusamitamab ravtansine versus docetaxel in previously treated CEACAM5-positive metastatic nonsquamous non-small-cell lung cancer
jRCT2080225013Phase 3Completed
- Sponsor
- Sanofi
- Start
- Jan 2020
- Modality
- Classical Binding Small Molecules → Small Molecules, Covalent Small Molecules → Small Molecules, Nucleic Acid-Directed Small Molecules → Small Molecules
01
Overview
Phase 3, randomised, open-label trial in non-small cell lung cancer (NSCLC) comparing Tusamitamab ravtansine arm with Docetaxel arm (2 arms). Started Jan 2020; status: completed.
02
Drugs
tusamitamab ravtansinedocetaxel
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on jRCT2080225013.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2080225013.